Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UFP Technologies, Inc. (UFPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices, and its filings offer detailed insight into its operations, financial performance, and risk profile in the medical device supply chain.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include information on net sales, gross profit, operating income, net income, segment performance, and non-GAAP measures such as organic sales growth, adjusted operating income, adjusted net income, and adjusted EBITDA. These filings also contain management’s discussion and analysis and risk factor sections that elaborate on topics referenced in the company’s press releases, including customer concentration, acquisition integration, supply chain and labor considerations, and regulatory and market risks.
Stock Titan also surfaces current reports on Form 8-K, where UFP Technologies furnishes earnings press releases and investor presentation materials under items such as Results of Operations and Financial Condition and Regulation FD Disclosure. These 8-Ks link the narrative in press releases to the formal SEC record and often include exhibits with detailed financial tables and reconciliations.
In addition to core periodic and current reports, users can monitor other SEC documents related to UFP Technologies, including any proxy materials and insider transaction reports when available. Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, highlight important changes from prior periods, and help readers quickly locate information on topics such as MedTech versus non-medical sales, acquisition impacts, and capital structure.
UFP Technologies, Inc. has called a virtual annual meeting for June 4, 2026 at 10:00 a.m. Eastern, where shareholders can vote online using a 16‑digit control number. The agenda includes electing seven directors for one‑year terms, an advisory vote on executive pay, and ratifying Grant Thornton LLP as independent auditor for 2026.
The proxy details a planned leadership transition: long‑time CEO R. Jeffrey Bailly will retire as Chief Executive Officer effective June 4, 2026 and, if re‑elected, become Executive Chairman, while President Mitchell C. Rock will become Chief Executive Officer. As of April 10, 2026, 7,736,939 shares of common stock were outstanding and entitled to one vote per share. The filing also highlights majority‑independent board and committees, stock ownership guidelines, an executive compensation clawback policy, prohibition on hedging and pledging company stock, and a pay program that combines salary, performance‑based cash bonuses, and time‑ and performance‑based restricted stock units tied to adjusted operating income targets.
Congress Asset Management filed a Schedule 13G reporting beneficial ownership of 5.4% of UFP Technologies Inc. common stock as of 03/31/2026. The filing shows 416,762 shares held with sole voting and dispositive power.
UFP Technologies Inc ownership filing shows The Vanguard Group reporting no beneficial ownership of Common Stock following an internal realignment.
The filing states Vanguard disaggregated certain subsidiaries and business divisions and will report holdings separately in reliance on SEC Release No. 34-39538; the reported amount beneficially owned is 0 shares (0%).
UFP Technologies director Thomas Oberdorf exercised stock options to acquire 2,864 common shares. He exercised options at an exercise price of $22.02 per share, converting them into the same number of common shares. Following the transaction, he directly holds 12,417 shares of UFP Technologies common stock, and this option grant is fully exercised with no remaining derivative position reported.
UFP Technologies Vice President Jason Holt reported a tax-related share disposition. On March 2, 2026, 478 shares of common stock were withheld at a price of $204.30 per share to cover tax liabilities arising from stock unit awards granted in 2023, 2024 and 2025 that vested on that date. After this withholding, Holt directly owned 8,978 shares of UFP Technologies common stock.
UFP Technologies Senior Vice President Christopher P. Litterio reported a tax‑related share disposition. On March 2, 2026, 815 shares of UFP Technologies common stock at a reference price of $204.30 per share were withheld to cover tax liabilities on stock unit awards granted in 2023, 2024 and 2025 that vested that day. After this tax-withholding disposition, he directly owned 11,977 shares of common stock.
UFP Technologies President Mitchell Rock reported a Form 4 showing a tax-related share disposition. On stock units that vested on March 2, 2026, 2,513 shares of common stock were withheld at $204.30 per share to cover tax liabilities, rather than being sold on the open market. After this withholding, Rock directly owns 36,220 shares of UFP Technologies common stock.
UFP Technologies Chief Financial Officer Ronald J. Lataille had 2,677 shares of common stock withheld on March 2, 2026 to cover tax liabilities tied to stock unit awards granted in 2023, 2024 and 2025. After this tax-withholding disposition, he directly owned 15,898 shares and also held 38,940 shares indirectly.
UFP Technologies CEO Jeffrey R. Bailly reported a Form 4 transaction showing a tax-withholding disposition of company stock rather than an open-market trade. On stock units that vested on March 2, 2026, 9,422 shares of common stock at $204.30 per share were withheld to cover tax liabilities. After this withholding, he directly owns 170,163 shares of UFP Technologies common stock. A footnote adds that he also has an indirect interest in 28,706 shares held by a trust, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.